Phase 3 Readout
IMDX: Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet
June 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2027
- Company
- Insight Molecular Diagnostics Inc. (IMDX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet
- Indication
- Alzheimer Disease